DarioHealth

DRIO

Market cap $78.4M

Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges More frequent engagement on the Dario platform associated with fewer inpatient and ER events  NEW YORK , Nov. 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal, evaluating healthcare utilization and medical costs among Dario users compared to matched non-users receiving usual care. The study, "Effects of a Digital Health Intervention for Adults with Type 2 Diabetes Mellitus on Health Care Resource Use and Health Care Charges in the United States: Retrospective Cohort Study," was not authored by Dario, but rather conducted by researchers at Sanofi and Symphony Health.

DarioHealth Corp. ( DRIO ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Zoe Harrison Erez Raphael - CEO & Director Steven Nelson - President & Chief Commercial Officer Chen Franco-Yehuda - CFO, Treasurer & Secretary Conference Call Participants Lucas Romanski - TD Cowen, Research Division Theodore O'Neill - Litchfield Hills Research, LLC Presentation Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2025 Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025.

DarioHealth Corp. (DRIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.63. This compares to a loss of $2.6 per share a year ago.

Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 million Exceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projected Strong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core B2B2C business, and $17.2 million, or 31%, reduction in operating expenses for the first nine months of 2025 compared to the same period in 2024 Dario's integrated whole-person digital health platform is driving adoption as more than 50% of Company's new clients are choosing the multi-condition offering—combining AI-driven personalization across diabetes, hypertension, weight management, musculoskeletal, and mental health Backed by $31.9 million in cash and cash equivalents on the balance sheet as of September 30, 2025, and accelerating commercial momentum, Dario expects to reach cashflow breakeven by late 2026 to early 2027 Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK , Nov. 13, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the third quarter ended September 30, 2025, along with strategic and commercial updates.

Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK , Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the presentation of research on new real-world evidence of medical cost reduction at ISPOR Europe 2025, one of the world's premier health economics and outcomes research conferences, currently taking place in Glasgow, Scotland.  The study, titled "Preliminary Observational Analysis of Digital Health Platform Associated with Medical Cost Changes in Employer Population," represents Dario's first publication using medical claims data to evaluate the economic impact of its multi-condition digital health platform (Dario has previously collaborated with clients to produce research demonstrating claims-based cost reduction).

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK , Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 3rd quarter ended September 30 th, 2025 and will host a conference call and webcast at 8:30 a.m.

NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating DarioHealth Corp. (NASDAQ: DRIO) on behalf of the company's shareholders.  The investigation seeks to determine whether DarioHealth's directors breached their fiduciary duties in connection with recent corporate actions.

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in DarioHealth (DRIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New clients span multiple industries and underscore broad increasing demand for Dario's multi-condition digital health platform Innovative new pricing model is highly attractive to prospective clients – supports Dario's continued market momentum and leading position as value-based solution provider NEW YORK , Oct. 13, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the addition of six (6) new employer clients to its growing portfolio, underscoring accelerating demand for integrated, multi-condition digital health solutions that improve health and reduce costs, as well as the deployment of a new pricing model that deepens the Company's value-based care strategy. This value-based pricing framework ties payments directly to member engagement and clinical progress – a structure that aims to help clients navigate costs by leveraging Dario's industry leading platform that delivers 5X return on investment ("ROI") and approximately $5,000 annual saving per Dario user.

Collaboration designed to drive measurable return on investment ("ROI") for health plans by reducing falls and improving outcomes for high-risk populations, including those with obesity and Medicare Advantage members with frailty and balance issues Generating more than $50 billion annually in direct medical costs, falls are one of the leading causes of injury among older adults in the U.S. NEW YORK , Oct. 6, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, and OneStep, the U.S. Food and Drug Administration ("FDA")-listed platform that delivers clinical-grade gait and mobility insights using only a smartphone, today announced a strategic collaboration to integrate OneStep's clinical-grade fall risk assessment and prevention capabilities within DarioHealth's digital health solutions ecosystem. The parties have signed a Memorandum of Understanding ("MOU") and expect to conclude a Master Services Agreement in the coming weeks.